Nurse Practitioner Program year 2022 Reported 2021–2022 Source: CMS Open Payments, 2026 publication

Keena Johnson-Bolden

Registered Nurse, Women's Health Care, Ambulatory Los Angeles, CA Nurse Practitioner

NPI 1780136820 CMS profile 10857126

400 W 30Th St, Los Angeles, CA 90007

Open in the dashboard

General payments

$106

6 records reported · program years 2021–2022

Research payments

$0

Paid to them · None reported · program years 2021–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Keena Johnson-Bolden of Los Angeles, CA is reported in the CMS Open Payments database as having received $106 across 6 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $30 2
2021 General $77 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Keena Johnson-Bolden
  • Registered Nurse, Women's Health Care, Ambulatory median
  • Middle half of Registered Nurse, Women's Health Care, Ambulatory
  • National median

In program year 2025, general payments to Keena Johnson-Bolden were reported at $0. Among 44 Registered Nurse, Women's Health Care, Ambulatory profiles paid that year, the median was $102 and the middle half received between $30 and $276.

Show as a table
Year Keena Johnson-Bolden Registered Nurse, Women's Health Care, Ambulatory median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $77 $156 $106–$276 $132
2022 $30 $155 $46–$289 $149
2023 $0 $117 $33–$282 $160
2024 $0 $69 $30–$246 $164
2025 $0 $102 $30–$276 $169

Breakdown

Who paid General payments · program years 2021–2022
  1. Novo Nordisk Inc $106 6 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2022
  1. Food and Beverage $106 6 payments
Products named General payments · program years 2021–2022
  1. Saxenda $38 2 payments
  2. Wegovy $34 2 payments
  3. RYBELSUS $20 1 payment
  4. Ozempic $20 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

94

Median for Nurse Practitioner: 389

Drug cost

$960

Median for Nurse Practitioner: $21,885

Branded share of claims

34%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Albuterol Sulfate Hfa Albuterol Sulfate Brand 20 $325
Cephalexin Generic 20 $191
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 12 $141
Azithromycin Generic 19 $122
Doxycycline Monohydrate Generic 12 $114
Ciprofloxacin Hcl Generic 11 $67

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Records

6 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Registered Nurse, Women's Health Care, Ambulatory in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record